Injection Site Reactions on Wegovy (Semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

What the trial numbers actually are

The safety database for the 2.4 mg weekly injection pools three randomized, double-blind, placebo-controlled trials: 2,116 adults treated with Wegovy for up to 68 weeks and 1,261 treated with placebo [1]. In that pooled set, injection site reactions were reported by 1.4% of Wegovy-treated patients and 1% of placebo-treated patients [1]. That is a 0.4 percentage point difference [1].

For scale, the same trials recorded nausea in 44% versus 16%, diarrhea in 30% versus 16%, and vomiting in 24% versus 6% [1]. Injection site reactions also do not appear in the label's summary list of adverse reactions occurring in 5% or more of patients, which runs through nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease and hair loss [1].

What the label does not break down

We found no severity breakdown or typical duration for injection site reactions in the Wegovy trial data; the label reports the category as a single rate [1].

What the label does record is why people stopped treatment. In the pooled weight-management trials, 6.8% of Wegovy-treated adults and 3.2% of placebo-treated adults discontinued permanently because of adverse reactions, and the most common reasons were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%) and diarrhea (0.7% versus 0.1%) [1]. Injection site reactions are not named among the leading causes of discontinuation [1].

Where the label says to inject

Wegovy is given once weekly, on the same day each week, at any time of day, with or without meals, into the abdomen, thigh or upper arm [1]. The label states that the time of day and the injection site can be changed without a dosage adjustment, so moving the injection to a different spot from one week to the next is within the labeled instructions [1].

Moving between these sites does not change drug exposure much. The label reports similar semaglutide exposure after injection in the abdomen, thigh and upper arm [1]. Semaglutide has a half-life of about one week and reaches peak levels roughly 1 to 3 days after a dose [1].

The label also asks patients to inspect the solution before each dose and use it only if it is clear, colorless and free of particles, and to be trained on the specific pen or syringe they are prescribed [1].

When a reaction is more than a local one

Wegovy is contraindicated in people who have had a serious hypersensitivity reaction to semaglutide or an ingredient in Wegovy; anaphylaxis and angioedema have been reported with Wegovy [1]. The Wegovy label's hypersensitivity warning states that anaphylactic reactions and angioedema have been reported in the postmarketing period, and the label says to discontinue Wegovy if a hypersensitivity reaction is suspected [1].

A review written for emergency clinicians notes that hypersensitivity, including injection site reactions, has been associated with GLP-1 receptor agonists, with reports of anaphylaxis and other rashes [2].

Does this apply to compounded semaglutide?

The 1.4% figure comes from trials of Wegovy 2.4 mg injection [1], so it does not describe compounded semaglutide. FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are marketed, and it has received reports of dosing errors with compounded injectable semaglutide [3].